Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2010
08/04/2010CN101791340A Method for purifying active ingredients of compound Naodesheng
08/04/2010CN101791337A Composition for treatment of vascular dementia and preparation method thereof
08/04/2010CN101791336A Extract from long pepper and preparation method and application thereof
08/04/2010CN101791335A Total alkaloid mixture sourcing from Chinese medicina plant lotus plumule and extraction and preparation method thereof
08/04/2010CN101791314A Application of crocin in preparing hypnotic drug
08/04/2010CN101791287A Solid oral drug composite containing aripiprazole microcrystalline
08/04/2010CN101066289B Medicine for treating Qi deficiency
08/04/2010CN101032603B Nerve meridians-activating wine
08/03/2010US7767786 Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
08/03/2010US7767683 Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
08/03/2010US7767679 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/03/2010US7767676 2-amino-3,6-dihydro-4-dimethyl-amino-6-ethyl-1,3,5-triazine hydrochloride; advanced glycosylation end-products inhibitor;antidiabetic, insulin resistance, neurodegenerative disorders, renal complications, atherosclerosis, angiopathy
08/03/2010US7767665 1,3-benzothiazinone derivatives and use thereof
08/03/2010US7767450 Nucleotide sequences coding voltage-gated transport proteins for use as screening tools to identify modulators for treatment and prevention of nervous, muscular, glandular, immune, reproductive and epithelial tissue disorders
08/03/2010US7767230 Organic compounds
08/03/2010US7767207 Interleukin-18 specific immunoglobulins for treatment and prevention of autoimmune, respiratory, reproductive, heart, connective tissue, liver, bone and arthritic disorders
08/03/2010CA2610873C Tetrahydroquinolines and their use as modulators of metabotropic glutamate receptors
08/03/2010CA2502582C Pharmaceutical formulation of olanzapine
08/03/2010CA2461426C Imidazo-pyrimidine derivatives as ligands for gaba receptors
08/03/2010CA2444269C Treatment of disorders secondary to organic impairments
08/03/2010CA2402199C Amidino compounds useful as nitric oxide synthase inhibitors
08/03/2010CA2312475C Method of suppressing .beta.-amyloid-related changes in alzheimer's disease
08/03/2010CA2306343C Novel aryloxy-alkyl-dialkylamines
08/03/2010CA2227706C Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
08/03/2010CA2190365C Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
07/2010
07/29/2010WO2010085799A2 Compositions and method for the treatment of parkinson's disease
07/29/2010WO2010085749A2 Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability
07/29/2010WO2010085724A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
07/29/2010WO2010085570A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
07/29/2010WO2010085352A2 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
07/29/2010WO2010085317A1 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
07/29/2010WO2010085027A1 Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
07/29/2010WO2010084999A1 Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
07/29/2010WO2010084798A1 Tricyclic compound
07/29/2010WO2010084797A1 Hetero atom-containing compound
07/29/2010WO2010084767A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
07/29/2010WO2010084661A1 Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound
07/29/2010WO2010084438A1 Amino-heterocyclic compounds used as pde9 inhibitors
07/29/2010WO2010084425A1 New adenosine receptor ligands and uses thereof
07/29/2010WO2010084356A1 Treatment of neurotrophic factor mediated disorders
07/29/2010WO2010084201A1 Novel derivative of erythromycin for the treatment and diagnosis of prion disease
07/29/2010WO2010084185A1 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use
07/29/2010WO2010084184A1 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use
07/29/2010WO2010084182A1 Methods for making valerenic acid derivatives and their use
07/29/2010WO2010084121A1 Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use
07/29/2010WO2010084120A1 N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands
07/29/2010WO2010065923A3 Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
07/29/2010WO2010064246A3 A mother-baby kit for treating emotional conditions before, during and after giving birth
07/29/2010WO2010060037A3 Adamantane modulators of nmda receptor and/or 5ht3 receptor
07/29/2010WO2010048164A3 N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
07/29/2010WO2010045212A3 Nicotinic acetylcholine receptor ligands and the uses thereof
07/29/2010WO2010007181A3 New salt forms of an aminoindan derivative
07/29/2010WO2010004535A3 Therapeutic methods and compositions employing peptide compounds
07/29/2010WO2009158467A3 Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
07/29/2010WO2009149487A3 Compounds for treating symptoms associated with parkinson's disease
07/29/2010WO2009143347A9 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
07/29/2010WO2009142594A9 The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
07/29/2010WO2009035159A8 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
07/29/2010US20100190861 Cycloalkylamines as monoamine reuptake inhibitors
07/29/2010US20100190859 Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis
07/29/2010US20100190836 Compounds, Screens, and Methods of Treatment
07/29/2010US20100190832 Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates
07/29/2010US20100190829 Renin inhibitors
07/29/2010US20100190825 Benzimidazoles which have activity at m1 receptor and their uses in medicine
07/29/2010US20100190824 Novel Substituted Piperidones as HSP Inducers
07/29/2010US20100190821 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors
07/29/2010US20100190819 alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof
07/29/2010US20100190817 Large substituent, non-phenolic amine opioids
07/29/2010US20100190813 Spiro [piperidine-4- 4' -thieno [3,2-c] pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
07/29/2010US20100190811 Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
07/29/2010US20100190808 Tricyclic Compounds As Modulators of TNF-alpha Synthesis
07/29/2010US20100190803 Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient
07/29/2010US20100190792 Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
07/29/2010US20100190790 Sigma receptor inhibitors
07/29/2010US20100190788 Amide derivatives as kinase inhitors
07/29/2010US20100190781 Sigma receptor inhibitors
07/29/2010US20100190780 Sigma receptor inhibitors
07/29/2010US20100190778 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use
07/29/2010US20100190776 Thiazoline and Oxazoline Derivatives and Their Methods of Use
07/29/2010US20100190773 Anti-Cytokine Heterocyclic Compounds
07/29/2010US20100190772 Substituted Azepine Derivatives As Serotonin Receptor Modulators
07/29/2010US20100190771 Amino-heterocyclic compounds
07/29/2010US20100190769 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
07/29/2010US20100190764 Novel compounds
07/29/2010US20100190763 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
07/29/2010US20100190759 Nk 1 antagonists
07/29/2010US20100190756 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
07/29/2010US20100190753 Methods and Compositions for Treating Amyloid-Related Diseases
07/29/2010US20100190752 tapentadol and antiepileptic such as gabapentin; synergistic pain relief
07/29/2010US20100190751 Novel combination of neramexane for treatment of nerordegeneratie disorders
07/29/2010US20100190749 Benzoxazole kinase inhibitors and methods of use
07/29/2010US20100190746 Quinazolinones as potassium channel modulators
07/29/2010US20100190730 Application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
07/29/2010US20100190728 Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents
07/29/2010US20100190725 Amino acid derivatives
07/29/2010US20100190722 Substance p and thyrotropin releasing hormone for therapeutic applications
07/29/2010US20100190718 Methods for preventing or treating mitochondrial permeability transition
07/29/2010US20100190717 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
07/29/2010US20100190716 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
07/29/2010US20100190713 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 1833